Representative Katy Hall proposes the following substitute bill:


1     
TRANSGENDER MEDICAL TREATMENTS AND PROCEDURES

2     
AMENDMENTS

3     
2023 GENERAL SESSION

4     
STATE OF UTAH

5     
Chief Sponsor: Michael S. Kennedy

6     
House Sponsor: Katy Hall

7     

8     LONG TITLE
9     General Description:
10          This bill enacts provisions regarding transgender medical treatments and procedures.
11     Highlighted Provisions:
12          This bill:
13          ▸     defines terms;
14          ▸     requires the Department of Health and Human Services to conduct a systematic
15     review of the medical evidence regarding hormonal transgender treatments and
16     provide recommendations to the Legislature;
17          ▸     requires the Division of Professional Licensing to create a certification for
18     providing hormonal transgender treatments;
19          ▸     requires a health care provider to meet certain requirements before providing a
20     hormonal transgender treatment;
21          ▸     prohibits a health care provider from providing a hormonal transgender treatment to
22     new patients who were not diagnosed with gender dysphoria before a certain date;
23          ▸     prohibits performing sex characteristic surgical procedures on a minor for the
24     purpose of effectuating a sex change;
25          ▸     specifies that an individual may bring a medical malpractice action related to certain

26     medical treatments and procedures;
27          ▸     specifies that an individual may disaffirm consent under certain circumstances;
28          ▸     allows an individual to bring a medical malpractice action for treatment provided to
29     the individual as a minor if the individual later disaffirms consent;
30          ▸     extends the medical malpractice statute of limitations related to providing certain
31     medical treatments and procedures; and
32          ▸     makes technical changes.
33     Money Appropriated in this Bill:
34          None
35     Other Special Clauses:
36          This bill provides a special effective date.
37          This bill provides revisor instructions.
38     Utah Code Sections Affected:
39     AMENDS:
40          58-67-102, as last amended by Laws of Utah 2022, Chapter 233
41          58-67-502, as last amended by Laws of Utah 2021, Chapter 337
42          58-68-102, as last amended by Laws of Utah 2022, Chapter 233
43          58-68-502, as last amended by Laws of Utah 2021, Chapter 337
44     ENACTS:
45          26B-1-214, Utah Code Annotated 1953
46          58-1-603, Utah Code Annotated 1953
47          58-1-603.1, Utah Code Annotated 1953
48          78B-3-427, Utah Code Annotated 1953
49     Utah Code Sections Affected by Revisor Instructions:
50          58-1-603.1, Utah Code Annotated 1953
51          78B-3-427, Utah Code Annotated 1953
52     

53     Be it enacted by the Legislature of the state of Utah:
54          Section 1. Section 26B-1-214 is enacted to read:
55          26B-1-214. Systematic medical evidence review of hormonal transgender
56     treatments.

57          (1) As used in this section, "hormonal transgender treatment" means the same as that
58     term is defined in Section 58-1-603.
59          (2) The department, in consultation with the Division of Professional Licensing created
60     in Section 58-1-103, the Physicians Licensing Board created in Section 58-67-201, the
61     Osteopathic Physician and Surgeon's Licensing Board created in Section 58-68-201, the
62     University of Utah, and a non-profit hospital system with multiple hospitals in Utah and
63     experience in specialty pediatric care, shall conduct a systematic medical evidence review
64     regarding the provision of hormonal transgender treatments to minors.
65          (3) The purpose of the systematic medical evidence review is to provide the Legislature
66     with recommendations to consider when deciding whether to lift the moratorium described in
67     Section 58-1-603.1.
68          (4) The systematic medical evidence review shall:
69          (a) analyze hormonal transgender treatments that are prescribed to a minor with gender
70     dysphoria, including:
71          (i) analyzing any effects and side effects of the treatment; and
72          (ii) whether each treatment has been approved by the federal Food and Drug
73     Administration to treat gender dsyphoria;
74          (b) review the scientific literature regarding hormonal transgender treatments in
75     minors, including short-term and long-term impacts, literature from other countries, and rates
76     of desistence and time to desistence where applicable;
77          (c) review the quality of evidence cited in any scientific literature including to analyze
78     and report on the quality of the data based on techniques such as peer review, selection bias,
79     self-selection bias, randomization, sample size, and other applicable best research practices;
80          (d) include high quality clinical research assessing the short-term and long-term
81     benefits and harms of hormonal transgender treatments prescribed to minors with gender
82     dysphoria and the short-term and long-term benefits and harms of interrupting the natural
83     puberty and development processes of the child;
84          (e) specify the conditions under which the department recommends that a treatment not
85     be permitted;
86          (f) recommend what information a minor and the minor's parent should understand
87     before consenting to a hormonal transgender treatment;

88          (g) recommend the best practices a health care provider should follow to provide the
89     information described in Subsection (4)(f);
90          (h) describe the assumptions and value determinations used to reach a
91     recommendation; and
92          (i) include any other information the department, in consultation with the entities
93     described in Subsection (2), determines would assist the Legislature in enacting legislation
94     related to the provision of hormonal transgender treatment to minors.
95          (5) Upon the completion of the systematic medical evidence review, the department
96     shall provide the systematic medical evidence review to the Health and Human Services
97     Interim Committee.
98          Section 2. Section 58-1-603 is enacted to read:
99          58-1-603. Hormonal transgender treatment on minors -- Requirements.
100          (1) As used in this section:
101          (a) "Approved organization" means an organization with expertise regarding
102     transgender health care for minors that is approved by the division.
103          (b) "Biological sex at birth" means an individual's sex, as being male or female,
104     according to distinct reproductive roles as manifested by sex and reproductive organ anatomy,
105     chromosomal makeup, and endogenous hormone profiles.
106          (c) "Disorder of sexual development" means a sexual development disorder where an
107     individual:
108          (i) is born with external biological sex characteristics that are irresolvably ambiguous;
109          (ii) is born with 46, XX chromosomes with virilization;
110          (iii) is born with 46, XY chromosomes with undervirilization;
111          (iv) has both ovarian and testicular tissue; or
112          (v) has been diagnosed by a physician, based on genetic or biochemical testing, with
113     abnormal:
114          (A) sex chromosome structure;
115          (B) sex steroid hormone production; or
116          (C) sex steroid hormone action for a male or female.
117          (d) "Health care provider" means:
118          (i) a physician;

119          (ii) a physician assistant licensed under Chapter 70a, Utah Physician Assistant Act; or
120          (iii) an advanced practice registered nurse licensed under Subsection 58-31b-301(2)(e).
121          (e) (i) "Hormonal transgender treatment" means administering, prescribing, or
122     supplying for effectuating or facilitating an individual's attempted sex change:
123          (A) to an individual whose biological sex at birth is female, a dose of testosterone or
124     other androgens at levels above those normally found in an individual whose biological sex at
125     birth is female;
126          (B) to an individual whose biological sex at birth is male, a dose of estrogen or a
127     synthetic compound with estrogenic activity or effect at levels above those normally found in
128     an individual whose biological sex at birth is male; or
129          (C) a puberty inhibition drug.
130          (ii) "Hormonal transgender treatment" does not include administering, prescribing, or
131     supplying a substance described in Subsection (1)(e)(i) to an individual if the treatment is
132     medically necessary as a treatment for:
133          (A) precocious puberty;
134          (B) endometriosis;
135          (C) a menstrual, ovarial, or uterine disorder;
136          (D) a sex-hormone stimulated cancer; or
137          (E) a disorder of sexual development.
138          (f) "Mental health professional" means any of the following:
139          (i) a physician who is board certified for a psychiatry specialization recognized by the
140     American Board of Medical Specialists or the American Osteopathic Association's Bureau of
141     Osteopathic Specialists;
142          (ii) a psychologist licensed under Chapter 61, Psychologist Licensing Act;
143          (iii) a clinical social worker licensed under Chapter 60, Part 2, Social Worker
144     Licensing Act;
145          (iv) a marriage and family therapist licensed under Chapter 60, Part 3, Marriage and
146     Family Therapist Licensing Act; or
147          (v) a clinical mental health counselor licensed under Chapter 60, Part 4, Clinical
148     Mental Health Counselor Licensing Act.
149          (g) "Minor" means an individual who is less than 18 years old.

150          (h) "Physician" means an individual licensed under:
151          (i) Chapter 67, Utah Medical Practice Act; or
152          (ii) Chapter 68, Utah Osteopathic Medical Practice Act.
153          (i) "Puberty inhibition drug" means any of the following alone or in combination with
154     aromatase inhibitors:
155          (i) gonadotropin-releasing hormone agonists; or
156          (ii) androgen receptor inhibitors.
157          (j) "Transgender treatment certification" means a certification described in Subsection
158     (2).
159          (2) (a) The division shall create a transgender treatment certification on or before July
160     1, 2023.
161          (b) The division may issue the transgender treatment certification to an individual if the
162     individual:
163          (i) is a health care provider or a mental health professional; and
164          (ii) has completed at least 40 hours of education related to transgender health care for
165     minors from an approved organization.
166          (c) The division may renew a transgender treatment certification:
167          (i) at the time an individual renews the individual's license; and
168          (ii) if the individual has completed at least 20 hours of continuing education related to
169     transgender health care for minors from an approved organization during the individual's
170     continuing education cycle.
171          (d) Beginning January 1, 2024, providing a hormonal transgender treatment to a minor
172     without a transgender treatment certification is unprofessional conduct.
173          (3) (a) A health care provider may provide a hormonal transgender treatment to a
174     minor only if the health care provider has been treating the minor for gender dysphoria for at
175     least six months.
176          (b) Beginning July 1, 2023, before providing a hormonal transgender treatment to a
177     minor described in Subsection (3)(a), a health care provider shall:
178          (i) determine if the minor has other physical or mental health conditions, identify and
179     document any condition, and consider whether treating those conditions before treating the
180     gender dysphoria would provide the minor the best long-term outcome;

181          (ii) consider whether an alternative medical treatment or behavioral intervention to
182     treat the minor's gender dysphoria would provide the minor the best long-term outcome;
183          (iii) document in the medical record that:
184          (A) the health care provider has complied with Subsections (3)(b)(i) and (ii); and
185          (B) providing the hormonal transgender treatment will likely result in the best
186     long-term outcome for the minor;
187          (iv) obtain written consent from:
188          (A) the minor; and
189          (B) the minor's parent or guardian unless the minor is emancipated;
190          (v) discuss with the minor:
191          (A) the risks of the hormonal transgender treatment;
192          (B) the minor's short-term and long-term expectations regarding the effect that the
193     hormonal transgender treatment will have on the minor; and
194          (C) the likelihood that the hormonal transgender treatment will meet the short-term and
195     long-term expectations described in Subsections (3)(b)(v)(B);
196          (vi) unless the minor is emancipated, discuss with the minor's parent or guardian:
197          (A) the risks of the hormonal transgender treatment;
198          (B) the minor's short-term and long-term expectations regarding the effect that the
199     hormonal transgender treatment will have on the minor;
200          (C) the parent or guardian's short-term and long-term expectations regarding the effect
201     that the hormonal transgender treatment will have on the minor; and
202          (D) the likelihood that the hormonal transgender treatment will meet the short-term and
203     long-term expectations described in Subsection (3)(b)(vi)(B) and (C);
204          (vii) document in the medical record that the health care provider has provided the
205     information described in Subsection (3)(b)(viii) and (ix);
206          (viii) provide the minor the following information if providing the minor a puberty
207     inhibition drug:
208          (A) puberty inhibition drugs are not approved by the FDA for the treatment of gender
209     dysphoria;
210          (B) possible adverse outcomes of puberty blockers are known to include diminished
211     bone density, pseudotumor cerebri and long term adult sexual dysfunction;

212          (C) research on the long-term risks to children of prolonged treatment with puberty
213     blockers for the treatment of gender dysphoria has not yet occurred; and
214          (D) the full effects of puberty blockers on brain development and cognition are
215     unknown;
216          (ix) provide the minor the following information if providing a cross-sex hormone as
217     described in Subsections (1)(e)(i)(A) or (B):
218          (A) the use of cross-sex hormones in males is associated with risks that include blood
219     clots, gallstones, coronary artery disease, heart attacks, tumors of the pituitary gland, strokes,
220     elevated levels of triglycerides in the blood, breast cancer, and irreversible infertility; and
221          (B) the use of cross-sex hormones in females is associated with risks of erythrocytosis,
222     severe liver dysfunction, coronary artery disease, hypertension, and increased risk of breast and
223     uterine cancers; and
224          (x) upon the completion of any relevant information privacy release, obtain a mental
225     health evaluation of the minor as described in Subsection (4).
226          (4) The mental health evaluation shall:
227          (a) be performed by a mental health professional who:
228          (i) beginning January 1, 2024, has a current transgender treatment certification; and
229          (ii) is not the health care provider that is recommending or providing the hormonal
230     transgender treatment;
231          (b) contain a determination regarding whether the minor suffers from gender dysphoria
232     in accordance with the fifth edition of the Diagnostic and Statistical Manual of Mental
233     Disorders;
234          (c) confirm that the minor and the mental health professional have had at least three
235     therapy sessions; and
236          (d) document all of the minor's mental health diagnoses and any significant life events
237     that may be contributing to the diagnoses.
238          (5) A violation of Subsection (3) is unprofessional conduct.
239          Section 3. Section 58-1-603.1 is enacted to read:
240          58-1-603.1. Hormonal transgender treatment moratorium.
241          (1) As used in this section:
242          (a) "Health care provider" means the same as that term is defined in Section 58-1-603.

243          (b) "Hormonal transgender treatment" means the same as that term is defined in
244     Section 58-1-603.
245          (2) A health care provider may not provide a hormonal transgender treatment to a
246     patient who:
247          (a) is a minor as defined in Section 58-1-603; and
248          (b) is not diagnosed with gender dysphoria before the effective date of this bill.
249          (3) A violation of Subsection (2) is unprofessional conduct.
250          Section 4. Section 58-67-102 is amended to read:
251          58-67-102. Definitions.
252          In addition to the definitions in Section 58-1-102, as used in this chapter:
253          (1) (a) "Ablative procedure" means a procedure that is expected to excise, vaporize,
254     disintegrate, or remove living tissue, including the use of carbon dioxide lasers and erbium:
255     YAG lasers.
256          (b) "Ablative procedure" does not include hair removal.
257          (2) "ACGME" means the Accreditation Council for Graduate Medical Education of the
258     American Medical Association.
259          (3) "Administrative penalty" means a monetary fine or citation imposed by the division
260     for acts or omissions determined to constitute unprofessional or unlawful conduct, in
261     accordance with a fine schedule established by the division in collaboration with the board, as a
262     result of an adjudicative proceeding conducted in accordance with Title 63G, Chapter 4,
263     Administrative Procedures Act.
264          (4) "Associate physician" means an individual licensed under Section 58-67-302.8.
265          (5) "Attempted sex change" means an attempt or effort to change an individual's body
266     to present that individual as being of a sex or gender that is different from the individual's
267     biological sex at birth.
268          (6) "Biological sex at birth" means an individual's sex, as being male or female,
269     according to distinct reproductive roles as manifested by:
270          (a) sex and reproductive organ anatomy;
271          (b) chromosomal makeup; and
272          (c) endogenous hormone profiles.
273          [(5)] (7) "Board" means the Physicians Licensing Board created in Section 58-67-201.

274          [(6)] (8) "Collaborating physician" means an individual licensed under Section
275     58-67-302 who enters into a collaborative practice arrangement with an associate physician.
276          [(7)] (9) "Collaborative practice arrangement" means the arrangement described in
277     Section 58-67-807.
278          [(8)] (10) (a) "Cosmetic medical device" means tissue altering energy based devices
279     that have the potential for altering living tissue and that are used to perform ablative or
280     nonablative procedures, such as American National Standards Institute (ANSI) designated
281     Class IIIb and Class IV lasers, intense pulsed light, radio frequency devices, and lipolytic
282     devices, and excludes ANSI designated Class IIIa and lower powered devices.
283          (b) Notwithstanding Subsection [(8)(a)] (10)(a), if an ANSI designated Class IIIa and
284     lower powered device is being used to perform an ablative procedure, the device is included in
285     the definition of cosmetic medical device under Subsection [(8)(a)] (10)(a).
286          [(9)] (11) "Cosmetic medical procedure":
287          (a) includes the use of cosmetic medical devices to perform ablative or nonablative
288     procedures; and
289          (b) does not include a treatment of the ocular globe such as refractive surgery.
290          [(10)] (12) "Diagnose" means:
291          (a) to examine in any manner another person, parts of a person's body, substances,
292     fluids, or materials excreted, taken, or removed from a person's body, or produced by a person's
293     body, to determine the source, nature, kind, or extent of a disease or other physical or mental
294     condition;
295          (b) to attempt to conduct an examination or determination described under Subsection
296     [(10)(a);] (12)(a);
297          (c) to hold oneself out as making or to represent that one is making an examination or
298     determination as described in Subsection [(10)(a);] (12)(a); or
299          (d) to make an examination or determination as described in Subsection [(10)(a)]
300     (12)(a) upon or from information supplied directly or indirectly by another person, whether or
301     not in the presence of the person making or attempting the diagnosis or examination.
302          [(11)] (13) "LCME" means the Liaison Committee on Medical Education of the
303     American Medical Association.
304          [(12)] (14) "Medical assistant" means an unlicensed individual who may perform tasks

305     as described in Subsection 58-67-305(6).
306          [(13)] (15) "Medically underserved area" means a geographic area in which there is a
307     shortage of primary care health services for residents, as determined by the Department of
308     Health and Human Services.
309          [(14)] (16) "Medically underserved population" means a specified group of people
310     living in a defined geographic area with a shortage of primary care health services, as
311     determined by the Department of Health and Human Services.
312          [(15)] (17) (a) (i) "Nonablative procedure" means a procedure that is expected or
313     intended to alter living tissue, but is not intended or expected to excise, vaporize, disintegrate,
314     or remove living tissue.
315          (ii) Notwithstanding Subsection [(15)(a)(i),] (17)(a)(i) nonablative procedure includes
316     hair removal.
317          (b) "Nonablative procedure" does not include:
318          (i) a superficial procedure as defined in Section 58-1-102;
319          (ii) the application of permanent make-up; or
320          (iii) the use of photo therapy and lasers for neuromusculoskeletal treatments that are
321     performed by an individual licensed under this title who is acting within the individual's scope
322     of practice.
323          [(16)] (18) "Physician" means both physicians and surgeons licensed under Section
324     58-67-301, Utah Medical Practice Act, and osteopathic physicians and surgeons licensed under
325     Section 58-68-301, Utah Osteopathic Medical Practice Act.
326          [(17)] (19) (a) "Practice of medicine" means:
327          (i) to diagnose, treat, correct, administer anesthesia, or prescribe for any human
328     disease, ailment, injury, infirmity, deformity, pain or other condition, physical or mental, real
329     or imaginary, including to perform cosmetic medical procedures, or to attempt to do so, by any
330     means or instrumentality, and by an individual in Utah or outside the state upon or for any
331     human within the state;
332          (ii) when a person not licensed as a physician directs a licensee under this chapter to
333     withhold or alter the health care services that the licensee has ordered;
334          (iii) to maintain an office or place of business for the purpose of doing any of the acts
335     described in Subsection [(17)(a)] (19)(a)(i) or (ii) whether or not for compensation; or

336          (iv) to use, in the conduct of any occupation or profession pertaining to the diagnosis or
337     treatment of human diseases or conditions in any printed material, stationery, letterhead,
338     envelopes, signs, or advertisements, the designation "doctor," "doctor of medicine,"
339     "physician," "surgeon," "physician and surgeon," "Dr.," "M.D.," or any combination of these
340     designations in any manner which might cause a reasonable person to believe the individual
341     using the designation is a licensed physician and surgeon, and if the party using the designation
342     is not a licensed physician and surgeon, the designation must additionally contain the
343     description of the branch of the healing arts for which the person has a license, provided that an
344     individual who has received an earned degree of doctor of medicine degree but is not a licensed
345     physician and surgeon in Utah may use the designation "M.D." if it is followed by "Not
346     Licensed" or "Not Licensed in Utah" in the same size and style of lettering.
347          (b) The practice of medicine does not include:
348          (i) except for an ablative medical procedure as provided in Subsection [(17)(b)(ii),]
349     (19)(b)(ii) the conduct described in Subsection [(17)(a)(i)] (19)(a)(i) that is performed in
350     accordance with a license issued under another chapter of this title;
351          (ii) an ablative cosmetic medical procedure if the scope of practice for the person
352     performing the ablative cosmetic medical procedure includes the authority to operate or
353     perform a surgical procedure; or
354          (iii) conduct under Subsection 58-67-501(2).
355          [(18)] (20) "Prescription device" means an instrument, apparatus, implement, machine,
356     contrivance, implant, in vitro reagent, or other similar or related article, and any component
357     part or accessory, which is required under federal or state law to be prescribed by a practitioner
358     and dispensed by or through a person or entity licensed under this chapter or exempt from
359     licensure under this chapter.
360          [(19)] (21) "Prescription drug" means a drug that is required by federal or state law or
361     rule to be dispensed only by prescription or is restricted to administration only by practitioners.
362          (22) (a) "Primary sex characteristic surgical procedure" means any of the following if
363     done for the purpose of effectuating or facilitating an individual's attempted sex change:
364          (i) for an individual whose biological sex at birth is male, castration, orchiectomy,
365     penectomy, vaginoplasty, or vulvoplasty;
366          (ii) for an individual whose biological sex at birth is female, hysterectomy,

367     oophorectomy, metoidioplasty, or phalloplasty; or
368          (iii) any surgical procedure that is related to or necessary for a procedure described in
369     Subsection (22)(a)(i) or (ii), that would result in the sterilization of an individual who is not
370     sterile.
371          (b) "Primary sex characteristic surgical procedure" does not include:
372          (i) surgery or other procedures or treatments performed on an individual who:
373          (A) is born with external biological sex characteristics that are irresolvably ambiguous;
374          (B) is born with 46, XX chromosomes with virilization;
375          (C) is born with 46, XY chromosomes with undervirilization;
376          (D) has both ovarian and testicular tissue; or
377          (E) has been diagnosed by a physician, based on genetic or biochemical testing, with a
378     sex development disorder characterized by abnormal sex chromosome structure, sex steroid
379     hormone production, or sex steroid hormone action for a male or female; or
380          (ii) removing a body part:
381          (A) because the body part is cancerous or diseased; or
382          (B) for a reason that is medically necessary, other than to effectuate or facilitate an
383     individual's attempted sex change.
384          (23) (a) "Secondary sex characteristic surgical procedure" means any of the following
385     if done for the purpose of effectuating or facilitating an individual's attempted sex change:
386          (i) for an individual whose biological sex at birth is male, breast augmentation surgery,
387     chest feminization surgery, or facial feminization surgery; or
388          (ii) for an individual whose biological sex at birth is female, mastectomy, breast
389     reduction surgery, chest masculinization surgery, or facial masculinization surgery.
390          (b) "Secondary sex characteristic surgical procedure" does not include:
391          (i) surgery or other procedures or treatments performed on an individual who:
392          (A) is born with external biological sex characteristics that are irresolvably ambiguous;
393          (B) is born with 46, XX chromosomes with virilization;
394          (C) is born with 46, XY chromosomes with undervirilization;
395          (D) has both ovarian and testicular tissue; or
396          (E) has been diagnosed by a physician, based on genetic or biochemical testing, with a
397     sex development disorder characterized by abnormal sex chromosome structure, sex steroid

398     hormone production, or sex steroid hormone action for a male or female; or
399          (ii) removing a body part:
400          (A) because the body part is cancerous or diseased; or
401          (B) for a reason that is medically necessary, other than to effectuate or facilitate an
402     individual's attempted sex change.
403          [(20)] (24) "SPEX" means the Special Purpose Examination of the Federation of State
404     Medical Boards.
405          [(21)] (25) "Unlawful conduct" means the same as that term is defined in Sections
406     58-1-501 and 58-67-501.
407          [(22)] (26) "Unprofessional conduct" means the same as that term is defined in
408     Sections 58-1-501 and 58-67-502, and as may be further defined by division rule.
409          Section 5. Section 58-67-502 is amended to read:
410          58-67-502. Unprofessional conduct.
411          (1) "Unprofessional conduct" includes, in addition to the definition in Section
412     58-1-501:
413          (a) using or employing the services of any individual to assist a licensee in any manner
414     not in accordance with the generally recognized practices, standards, or ethics of the
415     profession, state law, or division rule;
416          (b) making a material misrepresentation regarding the qualifications for licensure under
417     Section 58-67-302.7 or [Section] 58-67-302.8;
418          (c) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
419     Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
420          (d) violating the requirements of Title 26, Chapter 61a, Utah Medical Cannabis Act;
421     [or]
422          (e) falsely making an entry in, or altering, a medical record with the intent to conceal:
423          (i) a wrongful or negligent act or omission of an individual licensed under this chapter
424     or an individual under the direction or control of an individual licensed under this chapter; or
425          (ii) conduct described in Subsections (1)(a) through (d) or Subsection 58-1-501(1)[.];
426     or
427          (f) performing, or causing to be performed, upon an individual who is less than 18
428     years old:

429          (i) a primary sex characteristic surgical procedure; or
430          (ii) a secondary sex characteristic surgical procedure.
431          (2) "Unprofessional conduct" does not include:
432          (a) in compliance with Section 58-85-103:
433          (i) obtaining an investigational drug or investigational device;
434          (ii) administering the investigational drug to an eligible patient; or
435          (iii) treating an eligible patient with the investigational drug or investigational device;
436     or
437          (b) in accordance with Title 26, Chapter 61a, Utah Medical Cannabis Act:
438          (i) when registered as a qualified medical provider or acting as a limited medical
439     provider, as those terms are defined in Section 26-61a-102, recommending the use of medical
440     cannabis;
441          (ii) when registered as a pharmacy medical provider, as that term is defined in Section
442     26-61a-102, providing pharmacy medical provider services in a medical cannabis pharmacy; or
443          (iii) when registered as a state central patient portal medical provider, as that term is
444     defined in Section 26-61a-102, providing state central patient portal medical provider services.
445          (3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and
446     in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall define
447     unprofessional conduct for a physician described in Subsection (2)(b).
448          Section 6. Section 58-68-102 is amended to read:
449          58-68-102. Definitions.
450          In addition to the definitions in Section 58-1-102, as used in this chapter:
451          (1) (a) "Ablative procedure" means a procedure that is expected to excise, vaporize,
452     disintegrate, or remove living tissue, including the use of carbon dioxide lasers and erbium:
453     YAG lasers.
454          (b) "Ablative procedure" does not include hair removal.
455          (2) "ACGME" means the Accreditation Council for Graduate Medical Education of the
456     American Medical Association.
457          (3) "Administrative penalty" means a monetary fine imposed by the division for acts or
458     omissions determined to constitute unprofessional or unlawful conduct, as a result of an
459     adjudicative proceeding conducted in accordance with Title 63G, Chapter 4, Administrative

460     Procedures Act.
461          (4) "AOA" means the American Osteopathic Association.
462          (5) "Associate physician" means an individual licensed under Section 58-68-302.5.
463          (6) "Attempted sex change" means an attempt or effort to change an individual's body
464     to present that individual as being of a sex or gender that is different from the individual's
465     biological sex at birth.
466          (7) "Biological sex at birth" means an individual's sex, as being male or female,
467     according to distinct reproductive roles as manifested by:
468          (a) sex and reproductive organ anatomy;
469          (b) chromosomal makeup; and
470          (c) endogenous hormone profiles.
471          [(6)] (8) "Board" means the Osteopathic Physician and Surgeon's Licensing Board
472     created in Section 58-68-201.
473          [(7)] (9) "Collaborating physician" means an individual licensed under Section
474     58-68-302 who enters into a collaborative practice arrangement with an associate physician.
475          [(8)] (10) "Collaborative practice arrangement" means the arrangement described in
476     Section 58-68-807.
477          [(9)] (11) (a) "Cosmetic medical device" means tissue altering energy based devices
478     that have the potential for altering living tissue and that are used to perform ablative or
479     nonablative procedures, such as American National Standards Institute (ANSI) designated
480     Class IIIb and Class IV lasers, intense pulsed light, radio frequency devices, and lipolytic
481     devices and excludes ANSI designated Class IIIa and lower powered devices.
482          (b) Notwithstanding Subsection [(9)(a)] (11)(a), if an ANSI designated Class IIIa and
483     lower powered device is being used to perform an ablative procedure, the device is included in
484     the definition of cosmetic medical device under Subsection [(9)(a)] (11)(a).
485          [(10)] (12) "Cosmetic medical procedure":
486          (a) includes the use of cosmetic medical devices to perform ablative or nonablative
487     procedures; and
488          (b) does not include a treatment of the ocular globe such as refractive surgery.
489          [(11)] (13) "Diagnose" means:
490          (a) to examine in any manner another person, parts of a person's body, substances,

491     fluids, or materials excreted, taken, or removed from a person's body, or produced by a person's
492     body, to determine the source, nature, kind, or extent of a disease or other physical or mental
493     condition;
494          (b) to attempt to conduct an examination or determination described under Subsection
495     [(11)(a)] (13)(a);
496          (c) to hold oneself out as making or to represent that one is making an examination or
497     determination as described in Subsection [(11)(a)] (13)(a); or
498          (d) to make an examination or determination as described in Subsection [(11)(a)]
499     (13)(a) upon or from information supplied directly or indirectly by another person, whether or
500     not in the presence of the person making or attempting the diagnosis or examination.
501          [(12)] (14) "Medical assistant" means an unlicensed individual who may perform tasks
502     as described in Subsection 58-68-305(6).
503          [(13)] (15) "Medically underserved area" means a geographic area in which there is a
504     shortage of primary care health services for residents, as determined by the Department of
505     Health and Human Services.
506          [(14)] (16) "Medically underserved population" means a specified group of people
507     living in a defined geographic area with a shortage of primary care health services, as
508     determined by the Department of Health and Human Services.
509          [(15)] (17) (a) (i) "Nonablative procedure" means a procedure that is expected or
510     intended to alter living tissue, but is not expected or intended to excise, vaporize, disintegrate,
511     or remove living tissue.
512          (ii) Notwithstanding Subsection [(15)(a)(i)] (17)(a)(i), nonablative procedure includes
513     hair removal.
514          (b) "Nonablative procedure" does not include:
515          (i) a superficial procedure as defined in Section 58-1-102;
516          (ii) the application of permanent make-up; or
517          (iii) the use of photo therapy lasers for neuromusculoskeletal treatments that are
518     [preformed] performed by an individual licensed under this title who is acting within the
519     individual's scope of practice.
520          [(16)] (18) "Physician" means both physicians and surgeons licensed under Section
521     58-67-301, Utah Medical Practice Act, and osteopathic physicians and surgeons licensed under

522     Section 58-68-301, Utah Osteopathic Medical Practice Act.
523          [(17)] (19) (a) "Practice of osteopathic medicine" means:
524          (i) to diagnose, treat, correct, administer anesthesia, or prescribe for any human
525     disease, ailment, injury, infirmity, deformity, pain, or other condition, physical or mental, real
526     or imaginary, or to attempt to do so, by any means or instrumentality, which in whole or in part
527     is based upon emphasis of the importance of the musculoskeletal system and manipulative
528     therapy in the maintenance and restoration of health, by an individual in Utah or outside of the
529     state upon or for any human within the state;
530          (ii) when a person not licensed as a physician directs a licensee under this chapter to
531     withhold or alter the health care services that the licensee has ordered;
532          (iii) to maintain an office or place of business for the purpose of doing any of the acts
533     described in Subsection [(17)(a)] (19)(a)(i) or (ii) whether or not for compensation; or
534          (iv) to use, in the conduct of any occupation or profession pertaining to the diagnosis or
535     treatment of human diseases or conditions, in any printed material, stationery, letterhead,
536     envelopes, signs, or advertisements, the designation "doctor," "doctor of osteopathic medicine,"
537     "osteopathic physician," "osteopathic surgeon," "osteopathic physician and surgeon," "Dr.,"
538     "D.O.," or any combination of these designations in any manner which might cause a
539     reasonable person to believe the individual using the designation is a licensed osteopathic
540     physician, and if the party using the designation is not a licensed osteopathic physician, the
541     designation must additionally contain the description of the branch of the healing arts for which
542     the person has a license, provided that an individual who has received an earned degree of
543     doctor of osteopathic medicine but is not a licensed osteopathic physician and surgeon in Utah
544     may use the designation "D.O." if it is followed by "Not Licensed" or "Not Licensed in Utah"
545     in the same size and style of lettering.
546          (b) The practice of osteopathic medicine does not include:
547          (i) except for an ablative medical procedure as provided in Subsection [(17)(b)(ii)]
548     (19)(b)(ii), the conduct described in Subsection [(17)(a)(i)] (19)(a)(i) that is performed in
549     accordance with a license issued under another chapter of this title;
550          (ii) an ablative cosmetic medical procedure if the scope of practice for the person
551     performing the ablative cosmetic medical procedure includes the authority to operate or
552     perform a surgical procedure; or

553          (iii) conduct under Subsection 58-68-501(2).
554          [(18)] (20) "Prescription device" means an instrument, apparatus, implement, machine,
555     contrivance, implant, in vitro reagent, or other similar or related article, and any component
556     part or accessory, which is required under federal or state law to be prescribed by a practitioner
557     and dispensed by or through a person or entity licensed under this chapter or exempt from
558     licensure under this chapter.
559          [(19)] (21) "Prescription drug" means a drug that is required by federal or state law or
560     rule to be dispensed only by prescription or is restricted to administration only by practitioners.
561          (22) (a) "Primary sex characteristic surgical procedure" means any of the following if
562     done for the purpose of effectuating or facilitating an individual's attempted sex change:
563          (i) for an individual whose biological sex at birth is male, castration, orchiectomy,
564     penectomy, vaginoplasty, or vulvoplasty;
565          (ii) for an individual whose biological sex at birth is female, hysterectomy,
566     oophorectomy, metoidioplasty, or phalloplasty; or
567          (iii) any surgical procedure that is related to or necessary for a procedure described in
568     Subsection (22)(a)(i) or (ii), that would result in the sterilization of an individual who is not
569     sterile.
570          (b) "Primary sex characteristic surgical procedure" does not include:
571          (i) surgery or other procedures or treatments performed on an individual who:
572          (A) is born with external biological sex characteristics that are irresolvably ambiguous;
573          (B) is born with 46, XX chromosomes with virilization;
574          (C) is born with 46, XY chromosomes with undervirilization;
575          (D) has both ovarian and testicular tissue; or
576          (E) has been diagnosed by a physician, based on genetic or biochemical testing, with a
577     sex development disorder characterized by abnormal sex chromosome structure, sex steroid
578     hormone production, or sex steroid hormone action for a male or female; or
579          (ii) removing a body part:
580          (A) because the body part is cancerous or diseased; or
581          (B) for a reason that is medically necessary, other than to effectuate or facilitate an
582     individual's attempted sex change.
583          (23) (a) "Secondary sex characteristic surgical procedure" means any of the following

584     if done for the purpose of effectuating or facilitating an individual's attempted sex change:
585          (i) for an individual whose biological sex at birth is male, breast augmentation surgery,
586     chest feminization surgery, or facial feminization surgery; or
587          (ii) for an individual whose biological sex at birth is female, mastectomy, breast
588     reduction surgery, chest masculinization surgery, or facial masculinization surgery.
589          (b) "Secondary sex characteristic surgical procedure" does not include:
590          (i) surgery or other procedures or treatments performed on an individual who:
591          (A) is born with external biological sex characteristics that are irresolvably ambiguous;
592          (B) is born with 46, XX chromosomes with virilization;
593          (C) is born with 46, XY chromosomes with undervirilization;
594          (D) has both ovarian and testicular tissue; or
595          (E) has been diagnosed by a physician, based on genetic or biochemical testing, with a
596     sex development disorder characterized by abnormal sex chromosome structure, sex steroid
597     hormone production, or sex steroid hormone action for a male or female; or
598          (ii) removing a body part:
599          (A) because the body part is cancerous or diseased; or
600          (B) for a reason that is medically necessary, other than to effectuate or facilitate an
601     individual's attempted sex change.
602          [(20)] (24) "SPEX" means the Special Purpose Examination of the Federation of State
603     Medical Boards.
604          [(21)] (25) "Unlawful conduct" means the same as that term is defined in Sections
605     58-1-501 and 58-68-501.
606          [(22)] (26) "Unprofessional conduct" means the same as that term is defined in
607     Sections 58-1-501 and 58-68-502 and as may be further defined by division rule.
608          Section 7. Section 58-68-502 is amended to read:
609          58-68-502. Unprofessional conduct.
610          (1) "Unprofessional conduct" includes, in addition to the definition in Section
611     58-1-501:
612          (a) using or employing the services of any individual to assist a licensee in any manner
613     not in accordance with the generally recognized practices, standards, or ethics of the
614     profession, state law, or division rule;

615          (b) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
616     Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;
617          (c) making a material misrepresentation regarding the qualifications for licensure under
618     Section 58-68-302.5;
619          (d) violating the requirements of Title 26, Chapter 61a, Utah Medical Cannabis Act;
620     [or]
621          (e) falsely making an entry in, or altering, a medical record with the intent to conceal:
622          (i) a wrongful or negligent act or omission of an individual licensed under this chapter
623     or an individual under the direction or control of an individual licensed under this chapter; or
624          (ii) conduct described in Subsections (1)(a) through (d) or Subsection 58-1-501(1)[.];
625     or
626          (f) performing, or causing to be performed, upon an individual who is less than 18
627     years old:
628          (i) a primary sex characteristic surgical procedure; or
629          (ii) a secondary sex characteristic surgical procedure.
630          (2) "Unprofessional conduct" does not include:
631          (a) in compliance with Section 58-85-103:
632          (i) obtaining an investigational drug or investigational device;
633          (ii) administering the investigational drug to an eligible patient; or
634          (iii) treating an eligible patient with the investigational drug or investigational device;
635     or
636          (b) in accordance with Title 26, Chapter 61a, Utah Medical Cannabis Act:
637          (i) when registered as a qualified medical provider or acting as a limited medical
638     provider, as those terms are defined in Section 26-61a-102, recommending the use of medical
639     cannabis;
640          (ii) when registered as a pharmacy medical provider, as that term is defined in Section
641     26-61a-102, providing pharmacy medical provider services in a medical cannabis pharmacy; or
642          (iii) when registered as a state central patient portal medical provider, as that term is
643     defined in Section 26-61a-102, providing state central patient portal medical provider services.
644          (3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and
645     in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall define

646     unprofessional conduct for a physician described in Subsection (2)(b).
647          Section 8. Section 78B-3-427 is enacted to read:
648          78B-3-427. Transgender procedures upon a minor -- Right of action -- Informed
649     consent requirements -- Statute of limitations.
650          (1) As used in this section:
651          (a) "Hormonal transgender treatment" means the same as that term is defined in
652     Section 58-1-603.
653          (b) "Minor" means the same as that term is defined in Section 58-1-603.
654          (2) (a) Notwithstanding any other provision of law, a malpractice action against a
655     health care provider may be brought against a health care provider for damages arising from:
656          (i) providing a hormonal transgender treatment to a minor without complying with the
657     requirements described in Section 58-1-603;
658          (ii) negligence in providing a hormonal transgender treatment to a minor; or
659          (iii) providing a treatment or procedure described in Subsection (2)(b)(ii) to a minor
660     without the minor's consent including if the minor disaffirms consent under Subsection (3).
661          (3) (a) Notwithstanding any other provision of law, an individual who gave informed
662     consent as a minor or for whom consent was given under Section 78B-3-406, may disaffirm the
663     consent if:
664          (i) the treatment at issue began after the effective date of this bill;
665          (ii) the consent was provided for any of the following:
666          (A) a hormonal transgender treatment;
667          (B) a primary sex characteristic surgical procedure as defined in Section 58-67-102; or
668          (C) a secondary sex characteristic surgical procedure as defined in Section 58-67-102;
669          (iii) under the totality of the circumstances, a health care provider would have reason to
670     believe that the minor, or a similarly situated minor, could later regret having given consent;
671          (iv) the individual suffered a permanent physical injury; and
672          (v) the consent is disaffirmed in writing before the individual reaches the age of 25
673     years old.
674          (b) A disaffirmation of consent under this Subsection (3) relates back to the day the
675     original consent was given.
676          (4) Notwithstanding any other provision of law, a malpractice action against a health

677     care provider described in Subsection (2)(a) may be brought before the patient is 25 years old if
678     the treatment at issue in the malpractice action began, occurred, or continued on or after the
679     effective date of this bill.
680          (5) Sections 78B-3-404 and 78B-3-406 do not apply to an action described in this
681     section.
682          Section 9. Effective date.
683          If approved by two-thirds of all the members elected to each house, this bill takes effect
684     upon approval by the governor, or the day following the constitutional time limit of Utah
685     Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,
686     the date of veto override.
687          Section 10. Revisor instructions.
688          The Legislature intends that the Office of Legislative Research and General Counsel, in
689     preparing the Utah Code database for publication, replace each instance of the phrase "the
690     effective date of this bill" with the bill's actual effective date in the following Utah Code
691     sections:
692          (1) Section 58-1-603.1; and
693          (2) Section 78B-3-427.